Mit Bedacht kombinieren

Summary

Wechselwirkungen spielen beispielsweise in der Krebstherapie eine große Rolle, da die Patienten hier auf verschiedensten Wegen nach Linderung und Heilung suchen. 80 % aller onkologischen Patienten setzen klassische Medikamente sowie diverse Vitamine, Spurenelemente und Naturstoffe ein. Vor einer komplementären Tumortherapie gilt es daher, alle parallel eingenommenen Substanzen sowie die Ernährung des Patienten mitzuberücksichtigen.

Keywords

Krebstherapie - Interaktionen - Wechselwirkungen - Cytochrom-P450-Enzymsystem - pharmakokinetische Wechselwirkungen - pharmakodynamische Wechselwirkungen - pharmazeutische Wechselwirkungen - Prodrug - Topoisomerase - Tubulin-Polymerisation - monoklonale Antikörper - Lumisterol - Tachysterol - Pregnan-X-Rezeptor - Glutathiontransferasen - Alkylanzien - Antimetabolite - Anthrazykline - Mitosehemmstoffe - Antibiotika - Topoisomerasehemmer - Selen - Vitamin D - L-Carnitin - Coenzym Q10 - Ubichinon 10 - Aronia - Curcumin - Artemisin - Quercetin - Heilpilze

• Literatur

• 1 Alsanad SM, Howard RL, Williamson EM. An assessment of the impact of herb-drug combinations used by cancer patients. BMC Complement Altern Med 2016; 16 (01) 393
• 2 Alsanad SM, Williamson EM, Howard RL. Cancer patients at risk of herb / food supplement-drug interactions: a systematic review. Phytother Res 2014; 28 (12) 1749-1755
• 3 Andersen MR, Sweet E, Lowe KA. et al. Dangerous combinations: Ingestible CAM supplement use during chemotherapy in patients with ovarian cancer. J Altern Complement Med 2013; 19 (08) 714-720
• 4 Block KI, Koch AC, Mead MN. et al. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized trials. Int J Cancer 2008; 123 (06) 1227-1239
• 5 Böhm R, Haen E. Arzneimittelinteraktionen. Verstehen, vermitteln und vermeiden. Deutsche Apothekerzeitung 2012; 36: 64
• 6 Conklin KA. Cancer chemotherapy and antioxidants. J Nutr 2004; 134 (11) 3201-3204
• 7 Espey MG, Chen P, Chalmers B. et al. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med 2011; 50 (11) 1610-1619
• 8 Ferri N, Bellosta S, Baldessin L. et al. Pharmacokinetics interactions of monoclonal antibodies. Pharmacol Res 2016; 111: 592-599
• 9 Hoffer LJ, Levine M, Assouline S. et al. Phase I clinical trial of i. v. ascorbic acid in advanced malignancy. Ann Oncol 2008; 19 (11) 1969-1974
• 10 Loquai C, Dechent D, Garzarolli M. et al. Risk of interactions between complementary and alternative medicine and medication for comorbidities in patients with melanoma. Med Oncol 2016; 33 (05) 52
• 11 Loya AM, González-Stuart A, Rivera JO. Prevalence of polypharmacy, polyherbacy, nutritional supplement use and potential product interactions among older adults living on the United States-Mexico border: a descriptive, questionnaire-based study. Drugs Aging 2009; 26 (05) 423-436
• 12 Ma Y, Chapman J, Levine M. et al. High-dose parenteral ascorbate enhanced chemosensiti-vity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 2014; 6 (222) 222ra18
• 13 Masuda Y, Inoue M, Miyata A. et al. Maitake beta-glucan enhances therapeutic effect and reduces myelosupression and nephrotoxicity of cisplatin in mice. Int Immunopharmacol 2009; 9 (05) 620-626
• 14 Mooiman KD, Goey AK, Huijbregts TJ. et al. The in-vitro effect of complementary and alternative medicines on cytochrome P450 2C9 activity. J Pharm Pharmacol 2014; 66 (09) 1339-1346
• 15 Strippoli S, Lorusso V, Albano A. Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin. BMC Complement Altern Med 2013; 13: 199
• 16 Sweet ES Standish LJ, Goff BA. Adverse events associated with complementary and alternative medicine use in ovarian cancer patients. Integr Cancer Ther 2013; 12 (06) 508-516
• 17 Welsh JL, Wagner BA, van't Erve TJ. et al. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol 2013; 71 (03) 765-775
• 18 Yang J, Bogni A, Schuetz EG. et al. Etoposide pathway. Pharmacogenet Genomics 2009; 19 (07) 552-553